We provide you with 20 years of free, institutional-grade data for NVCR stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of NVCR. Explore the full financial landscape of NVCR stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2024-02-22 | 1645113 | NVCR | 10-K | Url |
| 2023-10-26 | 1645113 | NVCR | 10-Q | Url |
| 2023-07-27 | 1645113 | NVCR | 10-Q | Url |
| 2023-05-04 | 1645113 | NVCR | 10-Q | Url |
| 2023-02-23 | 1645113 | NVCR | 10-K | Url |
| 2022-10-27 | 1645113 | NVCR | 10-Q | Url |
| 2022-07-28 | 1645113 | NVCR | 10-Q | Url |
| 2022-04-28 | 1645113 | NVCR | 10-Q | Url |
| 2022-02-24 | 1645113 | NVCR | 10-K | Url |
| 2021-10-28 | 1645113 | NVCR | 10-Q | Url |
| 2021-07-29 | 1645113 | NVCR | 10-Q | Url |
| 2021-04-29 | 1645113 | NVCR | 10-Q | Url |
| 2021-02-25 | 1645113 | NVCR | 10-K | Url |
| 2020-10-29 | 1645113 | NVCR | 10-Q | Url |
| 2020-07-30 | 1645113 | NVCR | 10-Q | Url |
| 2020-04-30 | 1645113 | NVCR | 10-Q | Url |
| 2020-02-27 | 1645113 | NVCR | 10-K | Url |
| 2019-10-31 | 1645113 | NVCR | 10-Q | Url |
| 2019-07-25 | 1645113 | NVCR | 10-Q | Url |
| 2019-05-02 | 1645113 | NVCR | 10-Q | Url |
| 2019-02-28 | 1645113 | NVCR | 10-K | Url |
| 2018-10-25 | 1645113 | NVCR | 10-Q | Url |
| 2018-07-26 | 1645113 | NVCR | 10-Q | Url |
| 2018-04-26 | 1645113 | NVCR | 10-Q | Url |
| 2018-02-22 | 1645113 | NVCR | 10-K | Url |
| 2017-10-26 | 1645113 | NVCR | 10-Q | Url |
| 2017-07-27 | 1645113 | NVCR | 10-Q | Url |
| 2017-04-27 | 1645113 | NVCR | 10-Q | Url |
| 2017-02-23 | 1645113 | NVCR | 10-K | Url |
| 2016-11-02 | 1645113 | NVCR | 10-Q | Url |
| 2016-07-28 | 1645113 | NVCR | 10-Q | Url |
| 2016-05-10 | 1645113 | NVCR | 10-Q | Url |
| 2016-03-01 | 1645113 | NVCR | 10-K | Url |
| 2015-10-27 | 1645113 | NVCR | 10-Q | Url |
| 2015-08-31 | 1645113 | NVCR | S-1 | Url |
NovoCure Limited(NASDAQ:NVCR) 
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients wit...
Website: https://www.novocure.com/
Founded: 2000
Full Time Employees: 782
CEO: Asaf Danziger
Sector: Healthcare
Industry: Medical Instruments & Supplies
The information provided in this report about NVCR stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.